PATIENT ACCESS WORLD CONGRESS 2025 EUROPE
Improving Patient Access for Better Health Outcomes and Quality of Life
London, United Kingdom
Day 1 - Monday 20th October 2025
TRENDS & STRATEGIES IN PATIENT ACCESS
- Ensuring that patients can access products in a timely and affordable manner.
- Need to have access to data and insights early and often to make informed decisions about how pharma and biotech companies get their drugs to patients
- Digitizing healthcare to improve patient access
- Demonstrating cost-effectiveness of the product
- What is most important to patients?
Moderator:
Panelists:
Beverly Lui, Head, Patient Advocacy and Engagement International Region, Apellis
- Primary barriers why patients struggle to access the therapies they need
- Proactive steps life sciences companies can take to address these barriers
- Impact of not overcoming patient access hurdles
Steve Clark, Founder and Patient Advocate, Strive for Five
- How can we seize this opportunity to improve patient access to medicines?
- Assessing the impact of the regulation on national HTAs
- Strategic implications for health technology developers
- Its influence on price and reimbursement negotiations.
- Meeting growing demands for rigorous data requirements
- Understanding of increasingly diverse environment
- Strategic and adaptive approach in navigating complexities of different ecosystem
- Breaking down silo mentality
- Harmonizing access needs and aligning strategies at an early stage
- Advancing landscape and drivers in medical devices
- The importance of early and continuous stakeholder engagement
- How multi-stakeholder collaboration streamlines the path to market and guarantees that medical devices are thoroughly designed, tested, and deployed.
- Significance of patient-centered design on market access
- Prioritizing patient needs and preferences to enhance patient outcomes
- Adopting tech-powered tools that enables to have a more direct relationship with HCPs and the patients they serve
- Innovative technologies that make patient-focused approaches scalable and efficient
Josie Godfrey, Co-Founder and CEO, Realise Advocacy
KEY ASPECTS TO PATIENT ACCESS
- Key trends that will affect the European biopharmaceutical market access landscape
- Impact of both the EU’s industrial pharma policy and the health technology assessment (HTA) landscape
- Overcoming the increasing constraints on government healthcare budgets
- Fundamental policy changes affecting the industry
- Addressing the payer activation and reimbursement challenges
- The impact of regulatory roadblocks and competition
- Overcoming the issue on inadequate market adoption by HCPs
- Patient engagement and adoption challenges
Katja Berg, Global Value and Access Strategy, BBU, AstraZeneca
- Varying framework in place to improve patient access to innovative medicines
- Considerations for a suitable pharmaceutical regulatory and clinical framework
- How regulation can help to unlock the potential of innovative medicines
- Streamlined regulatory framework bringing breakthroughs to patients faster
- The role of IEP in drug development
- Integration of various analytical techniques
- Challenges in implementing IEP
- Evolving role of real-world evidence is emphasized, advocating for IEP
- Bullet points to follow
Marta Contente, Sr Director, Pipeline Head of Immunology, GHEVO, TEVA
- Ensuring that patients have access to the right treatments at the right time and fair price that aligns with the effectiveness of a drug in treating disease
- Establishing pricing and reimbursement sustainability for both the pharmaceutical manufacturer and the healthcare payer
- Incorporating patient input to ensure that their drugs address the specific needs, preferences, and quality of life concerns of patients.
- Collaborative, patient-centric care approach that enhances the quality of life for patients with complex chronic conditions
- Removing barriers to treatment and improving patient access to essential therapies.
Panellist: Beverly Lui, Head, Patient Advocacy and Engagement International Region, Apellis